Patents Examined by Pancham Bakshi
  • Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
    Patent number: 11667910
    Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).
    Type: Grant
    Filed: February 3, 2022
    Date of Patent: June 6, 2023
    Assignee: CureVac Manufacturing GmbH
    Inventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
  • Pivarubicin and benzarubicin compositions
    Patent number: 11666589
    Abstract: The present invention relates to compositions comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and methods for using the compositions in the treatment of triple negative breast cancer (TNBC) by administering an effective amount of the compositions to a subject. In some instances, the subject is a mammal, including at least one of human, feline, and canine mammals.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: June 6, 2023
    Inventors: Leonard Lothstein, Judith Soberman, Tiffany N. Seagroves
  • N-3 immunoresolvents: structures and actions
    Patent number: 11667598
    Abstract: The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 6, 2023
    Assignee: The Brigham & Women's Hospital Inc.
    Inventors: Charles N. Serhan, Jesmond Dalli
  • Carbohydrate conjugates as delivery agents for oligonucleotides
    Patent number: 11666653
    Abstract: The present invention provides a modified RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand targets an HBV mRNA; all of the nucleotide sugars of the RNAi agent are 2?-modified; and at least one of the sense and antisense strands is conjugated to at least one targeting ligand that comprises two or more building blocks connected to a biantennary or triantennary branched linker, optionally via one or more linking groups.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: June 6, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Martin Maier
  • Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
    Patent number: 11666592
    Abstract: The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: June 6, 2023
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Michio Hirano, Caterina Garone, Ramon Marti
  • Low dose combination CDA substrate drug/cedazuridine with extended administration
    Patent number: 11660310
    Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: May 30, 2023
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Harold Keer, Mohammad Azab, Aram Oganesian
  • Treatment of Rett syndrome
    Patent number: 11660306
    Abstract: The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: May 30, 2023
    Assignee: Cold Spring Harbor Laboratory
    Inventors: Nicholas Tonks, Navasona Krishnan
  • Prodrug-type anticancer agent using cancer-specific enzymatic activity
    Patent number: 11655269
    Abstract: To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: May 23, 2023
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Yasuteru Urano, Mako Kamiya, Kento Hayashi
  • Complexes
    Patent number: 11649258
    Abstract: The present invention provides a palladium(II) complex of formula (1). R12, m, and X are described in the specification. The invention also provides a process for the preparation of the complex, and its use in carbon-carbon and carbon-heteroatom coupling reactions.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: May 16, 2023
    Assignee: Johnson Matthey Public Limited Company
    Inventors: Thomas Colacot, Ruishan Chow, Andrew Jon DeAngelis
  • Purification method of high-purity n-tetrasilane
    Patent number: 11649168
    Abstract: A high-purity n-tetrasilane purification method includes: introducing a tetrasilane (Si4H10) isomeric mixture into a solidifying purification tank, cooling the tetrasilane (Si4H10) to a predetermined temperature with refrigerant in the solidifying purification tank, maintaining the predetermined temperature between the freezing temperature of the n-tetrasilane (n-Si4H10) and of the i-tetrasilane (i-Si4H10), solidifying the n-tetrasilane (n-Si4H10) in the tetrasilane (Si4H10) isomeric mixture into solid state, and vacuuming the i-tetrasilane (i-Si4H10) from the mixture for separation.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 16, 2023
    Assignee: Taiwan Speciality Chemicals Corporation
    Inventors: Sung-Yueh Shieh, Teng-Chih Lee
  • Chiral control
    Patent number: 11643657
    Abstract: The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: May 9, 2023
    Assignee: WAVE LIFE SCIENCES LTD.
    Inventors: David Charles Donnell Butler, Naoki Iwamoto, Meena, Nenad Svrzikapa, Gregory L. Verdine, Ivan Zlatev
  • Methods of treating sepsis using anti-sepsis lipid A (ASLA) based therapeutics
    Patent number: 11633411
    Abstract: The present invention provides a method of treating sepsis in a subject, comprising administering to the subject an effective amount of a compound of the formula wherein R1 and R2 may be H, OH, protonated phosphate, a phosphate salt, a sugar phosphonate, or a mono-, di- or poly-saccharide, R3 may be OH or a mono-, di- or poly-saccharide, R4, R5, R6 and R7 may be an alkyl or alkenyl chain of up to 13 carbons (for a chain of 16 carbons), and R8, R9, R10 and R11 may be H, OH, or an alkyl or alkenyl ester of up to 16 carbons, or a salt thereof.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: April 25, 2023
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Robert K. Ernst, Erin M. Harberts, Alison J. Scott
  • Water-soluble, high-molecular-weight chitosan powders
    Patent number: 11634561
    Abstract: The poor water solubility of high molecular weight chitosan has limited its use in areas such as food and beverage products, post-harvest treatments, cosmetic and pharmaceutical products, medical treatments, and environmental pollution treatments. Disclosed is a high-molecular-weight, solid-state chitosan powder that is completely water-soluble.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: April 25, 2023
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Witoon Prinyawiwatkul, Zhimin Xu, Yixiao Shen
  • RUNX2 transcription factor inhibitors and uses thereof
    Patent number: 11634381
    Abstract: Provide herein are compounds with a general chemical structure of: Substituents R1 and R2 independently are H, Cl, F, Br, CH3, CF3, SH, —N(C1-3alkyl)2, —NHC(O)C1-3alkyl, or —NHC(O)C5-7cycloalkyl, substituent R3 is H or C1-3 alkyl and R4 is a bridged cycloalkene such as a bridged cyclohexene or a bridge-substituted cyclohexene. The compounds are therapeutics to treat a cancer, such as breast cancer, or metastatic cancers, to inhibit RUNX2 activity, such as protein expression, in a cancer cell and to increase survival of a subject with breast cancer.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: April 25, 2023
    Assignees: University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Antonino Passaniti, Alexander D. MacKerell, Jr.
  • Therapeutic methods and compositions for treating pancreatic cancer using 6,8-bis-benzylthio-octanoic acid
    Patent number: 11622950
    Abstract: The invention provides methods, compositions, and medical kits for treating pancreatic cancer using (i) 6,8-bis(benzylsulfanyl)octanoic acid or a pharmaceutically acceptable salt thereof in combination with (ii) gemcitabine or a pharmaceutically acceptable salt thereof, and (iii) nab-paclitaxel.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: April 11, 2023
    Assignee: Cornerstone Pharmaceuticals, Inc.
    Inventors: Sanjeev Luther, Robert G. L. Shorr
  • Compositions comprising sulfated polysaccharides
    Patent number: 11617762
    Abstract: The present invention provides a synergistic anti-inflammatory composition comprising one more anti-inflammatory agents such as a steroid, non-steroidal anti-inflammatory drug (NSAID) or a cannabinoid in combination with one or more sulfated polysaccharides. The invention is further directed to a method of treating inflammation and inflammatory diseases using said synergistic composition.
    Type: Grant
    Filed: December 10, 2017
    Date of Patent: April 4, 2023
    Assignee: Seanergy Dermatology Ltd.
    Inventor: Doron Friedman
  • Combined administration of cysteine-aspartic protease inhibitors with P2Y12 receptor antagonists protects the heart against myocardial infarction
    Patent number: 11612615
    Abstract: The present disclosure generally pertains to methods of treating myocardial infarct involving administering a platelet anti-aggregate, a cysteine-aspartic protease inhibitor, and reperfusion therapy. In certain embodiments, the platelet anti-aggregate is at least one P2Y12 receptor antagonist or Glycoprotein IIb/IIIa inhibitor, the cysteine-aspartic protease inhibitor is selected from the group consisting of Caspase-1, 4, 5, 11 and 12 inhibitors, and reperfusion therapy is percutaneous coronary intervention. In certain embodiments, the at least one P2Y12 receptor antagonist is selected from the group consisting of cangrelor, ticagrelor, clopidogrel and prasugrel. The disclosed methods provide an improved cardioprotective effect against infarction when compared with the current standard of care.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 28, 2023
    Assignee: The University of South Alabama
    Inventors: Jonathon P. Audia, James M. Downey, Diego Alvarez, Michael V. Cohen
  • Compositions and methods comprising conductive metal organic frameworks and uses thereof
    Patent number: 11608350
    Abstract: Compositions and methods comprising metal organic frameworks (MOFs) and related uses are generally provided. In some embodiments, a MOF comprises a plurality of metal ions, each coordinated with at least one ligand comprising at least two sets of ortho-diimine groups arranged about an organic core.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Mircea Dinca, Dennis Sheberla, Lei Sun, Casey R. Wade, Michael Glenn Campbell
  • Preparation method of functional silanes
    Patent number: 11608348
    Abstract: A preparation method of functional silanes comprises: substance A and substance B are added in a three-necked bottle and a certain amount of solvent is added; the resultant mixture is stirred for 0.5-24 h in the presence of catalyst under an atmosphere of argon, resulting in the crude product; after removing the remaining solvent and catalyst, the residual product is purified by chromatographic column to obtain functional silanes; the substance A is an alkene-containing silane and the substance B is an alcohol; functional silanes with various structures can be prepared, and their structures can be controlled by regulating the ratio of substance A and substance B, thereby providing ideas for the preparation of different silanes and the structural design of silane coupling agents.
    Type: Grant
    Filed: June 27, 2022
    Date of Patent: March 21, 2023
    Assignee: SHANDONG UNIVERSITY
    Inventors: Dengxu Wang, Rui Wang, Shengyu Feng
  • Hepatitis B antiviral agents
    Patent number: 11596611
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: March 7, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yao-Ling Qiu, Xuri Gao, Jorden Kass, Hui Cao, Wei Li, Xiaowen Peng, Byung-Chul Suh, Yat Sun Or